http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100976062-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-365 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 |
| filingDate | 2008-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2010-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2010-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-100976062-B1 |
| titleOfInvention | Method of stabilization of orlistat preparations |
| abstract | According to the present invention, the particle size is adjusted to have an average particle size of 1-400 μm of orlistat as an active ingredient, so that the activity of the orlistat-containing formulation does not cause deactivation or lowering of titer due to chemical stability and low solubility of orlistat. It relates to a stabilization method.n n n Orlistat having a particle size according to the present invention is not only a chemically stable drug that does not produce a flexible material, but also maintains crystallinity when formulated, and has excellent storage stability, and despite low solubility of orlistat itself. By exhibiting a high dissolution rate, it is possible to provide an oral formulation of orlistat which can increase bioavailability.n n n n Orlistat, Microparticles, Leading Materials, Dissolution Rate |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019009577-A1 |
| priorityDate | 2008-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 50.